On April 20, Deng Boqing, deputy director of the China International Development Cooperation Agency, said at the 2022 Boao Forum for Asia Annual Conference that the treatment of new coronary pneumonia should start from several aspects.
The first is healthy living habits, such as maintaining social distance, wearing masks, and washing hands frequently; the second is vaccine prevention, but the treatment of critically ill patients with COVID-19 still relies on specific medicines. The Chinese government has made a lot of efforts in this regard.
Traditional Chinese medicine has "three drugs and three prescriptions". Now there are some small molecule drugs, some monoclonal antibodies and polyclonal antibodies are also being developed or clinically tested, and some results have been achieved.
China is not completely following in these aspects, and in some aspects it is already leading or running at the same time.
(Reporter Liu Chao and Wu Xu produced Le Xiaomin)
Responsible editor: [Chen Haifeng]